Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
gov Paper 9
Tel: 571-272-7822 Entered: January 11, 2018
v.
INCYTE CORPORATION,
Patent Owner.
_______________
Case PGR2017-00034
Patent 9,662,335 B2
_______________
DECISION
Denying Institution of Post-Grant Review
37 C.F.R. § 42.208
PGR2017-00034
Patent 9,662,335 B2
I. INTRODUCTION
A. Related Proceedings
2
PGR2017-00034
Patent 9,662,335 B2
C. Challenged Claims
3
PGR2017-00034
Patent 9,662,335 B2
1
The relevant post-grant review provisions of the America Invents Act
(“AIA”), Pub. L. No. 112-29, 125 Stat. 284 (2011), took effect on March 16,
2013. 125 Stat. at 293, 311. Because the application from which the ’335
patent issued was filed after that date, our citations to Title 35 are to its post-
AIA version. Section 4(c) of the AIA re-designated 35 U.S.C. §§ 112(1), (2)
as 35 U.S.C. §§ 112(a), (b), respectively, effective September 16, 2012. 125
Stat. at 296–297.
2
Ex. 1004, Silverman, I., et al., WO 2013/188783 (filed on June 14, 2013;
published on December 19, 2013)
4
PGR2017-00034
Patent 9,662,335 B2
II. ANALYSIS
5
PGR2017-00034
Patent 9,662,335 B2
date before March 16, 2013, then the ’335 patent is not eligible for post-
grant review. In this regard, Petitioner asserts that none of the challenged
claims were adequately enabled or described in any parent application, “each
of which shares the same specification as the ’335 patent,” or any
provisional application. Pet. 12–20. Petitioner therefore asserts that each
challenged claim has an effective filing date of June 3, 2016, which is the
actual filing date of the ’335 patent. Id.
Upon consideration of the Petition and Preliminary Response, as well
as all supporting evidence, we are persuaded, for the reasons that follow, that
the challenged claims are entitled to a priority date of at least December 12,
2006, the earliest filed non-provisional parent application. Therefore, based
on the current record, the ’335 patent is not eligible for post-grant review.
B. Claim Interpretation
6
PGR2017-00034
Patent 9,662,335 B2
v. Proxyconn, Inc., 789 F.3d 1292, 1298 (Fed. Cir. 2015) (overruled on other
grounds by Aqua Products, Inc. v. Matal, 872 F.3d 1290 (Fed. Cir. 2017)).
Petitioner construes “one or more hydrogen atoms” of ruxolitinib in
the claims to mean that “any one or any combination of the 18 hydrogen
atoms of ruxolitinib may be replaced with deuterium.” Pet. 11. In this
regard, Patent Owner does not dispute Petitioner’s construction. Prelim.
Resp. 12. We adopt Petitioner’s proposed construction of “one or more
hydrogen atoms” for the purposes of this decision.
We determine that no explicit construction of any other claim term is
necessary to determine whether to institute a trial in this case.
3
As noted above, Petitioner asserts post-grant review eligibility based on the
argument that each of the challenged claims lacks written description
support in any parent non-provisional application or any provisional
application. Pet. 12–20. Petitioner acknowledges that “each [non-
provisional parent application] shares the same specification as the ’335
patent.” Id. at 20. Accordingly, we reference the ’335 patent specification
in our analysis of whether the challenged claims have written description
support in the parent applications.
7
PGR2017-00034
Patent 9,662,335 B2
8
PGR2017-00034
Patent 9,662,335 B2
9
PGR2017-00034
Patent 9,662,335 B2
10
PGR2017-00034
Patent 9,662,335 B2
even a single embodiment within the scope of the claims”); id. at 23 (“The
genus is vast because the claims do not specify substitution of any particular
hydrogen atom . . . , but instead, include every possible combination of one
to 18 deuterium replacements.” (citing Ex. 1002 ¶¶ 75–79, 82–84, 91, 150)).
Petitioner further contends as follows:
Id. at 28–29 (emphasis added); see also Ex. 1002 ¶¶ 45, 57, 61, 87, 95, 116,
119, 134, 136, 140 (testifying that replacement of the hydrogen atoms with a
deuterium atom would lead to inseparable mixtures of deuterated analogs).
Thus, according to Petitioner, “it would have required undue
experimentation to make the full scope of the claimed invention.” Id. at 21.
For the reasons set forth on pages 26–43 of the Preliminary Response,
which we adopt, we are not persuaded by Petitioner’s arguments and
11
PGR2017-00034
Patent 9,662,335 B2
12
PGR2017-00034
Patent 9,662,335 B2
E. Anticipation by Silverman
Petitioner’s anticipation challenge is asserted based on the assumption
that the challenged claims are not entitled to an effective filing date earlier
than June 3, 2016. As discussed above, Petitioner fails to carry its burden to
show lack of written description or non-enablement. As such, Petitioner
failed to establish that the ’335 patent is eligible for post-grant review and
that Silverman is prior art.
III. CONCLUSION
For the foregoing reasons, we determine that the Petitioner has not
demonstrated that claims 1–6 lack § 112 support in any parent non-
provisional application to which the ’335 patent claims priority. Thus,
13
PGR2017-00034
Patent 9,662,335 B2
Petitioner has failed to show that the effective filing date of any one of
claims 1–6 is after the effective date of the AIA.
IV. ORDER
It is
ORDERED that the Petition is denied and no trial is instituted.
14
PGR2017-00034
Patent 9,662,335 B2
PETITIONER:
Deborah Sterling
dsterlin-ptab@skgf.com
Robert Millonig
bobm-ptab@skgf.com
Marsha Gillentine
mgillentine-ptab@skgf.com
Jeremiah Frueauf
jfrueauf-ptab@skgf.com
PATENT OWNER:
Thomas Irving
tom.irving@finnegan.com
Mark Feldstein
mark.feldstein@finnegan.com
Maureen Queler
maureen.queler@finnegan.com
Christopher McDavid
christopher.mcdavid@finnegan.com
15